GLS and benign prostatic hyperplasia: The different effects of GLS1 and MYC inhibition in cancer and benign prostate hyperplasia cells can be in part explained by unique metabolic characteristics of normal prostate epithelial cells such as truncated TCA cycle, OXPHOS-deficiency, and high dependence on glycolysis for energy production 4.